Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ring chromosome 3 syndrome is a rare chromosomal anomaly syndrome with a highly variable phenotype principally characterized by pre- and postnatal growth retardation, short stature, developmental delay, mild to severe intellectual disability, microcephaly and mild dysmorphic features (incl. triangular face, dysplastic ears, upslanting palpebral fissures, epicanthic folds, broad nasal bridge, full nasal tip, long philtrum, downturned corners of the mouth, and micro/retrognathia). Additional manifestations reported include hypotonia, mild articular limitation, hearing loss, digital anomalies (i.e. clinodacytyly, brachydactyly), café-au-lait patches and hypospadias.
Biomarker and diagnostic research for ring chromosome 3 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ring chromosome 3.
145 publications have been identified in PubMed for ring chromosome 3. Kisho has analyzed 93 by research type. Research spans Epidemiology / Natural History (35%), Basic Science / Preclinical (31%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 33 | 35% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research
29 |
31% |
Clinical study results | 11 | 12% |
Research summaries | 10 | 11% |
Testing and diagnosis research | 6 | 6% |
Patient case studies | 2 | 2% |
New treatment approaches | 2 | 2% |
Howick V JF (2026). [PMID: 42158619](https://pubmed.ncbi.nlm.nih.gov/42158619/). *Mayo Clin Proc Innov Qual Outcomes*. [Epidemiology / Natural History]
George BM (2026). [PMID: 40269321](https://pubmed.ncbi.nlm.nih.gov/40269321/). *Nat Biotechnol*. [Gene Therapy / Novel Therapeutics]
Gao A (2026). [PMID: 41005926](https://pubmed.ncbi.nlm.nih.gov/41005926/). *J Environ Sci (China)*. [Epidemiology / Natural History]
Yuxi L (2026). [PMID: 41496676](https://pubmed.ncbi.nlm.nih.gov/41496676/). *Ophthalmic Epidemiol*. [Epidemiology / Natural History]
Benigni A (2026). [PMID: 41076080](https://pubmed.ncbi.nlm.nih.gov/41076080/). *Kidney Int*. [Basic Science / Preclinical]
Dhaenens L (2026). [PMID: 41965201](https://pubmed.ncbi.nlm.nih.gov/41965201/). *Reprod Biomed Online*. [Clinical Trial Publication]
Elizabeth MV (2026). [PMID: 41538134](https://pubmed.ncbi.nlm.nih.gov/41538134/). *Luminescence*. [Basic Science / Preclinical]
Merkel MFR (2026). [PMID: 41388235](https://pubmed.ncbi.nlm.nih.gov/41388235/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Lu X (2026). [PMID: 41484691](https://pubmed.ncbi.nlm.nih.gov/41484691/). *J Health Popul Nutr*. [Epidemiology / Natural History]
Aczel B (2026). [PMID: 41922703](https://pubmed.ncbi.nlm.nih.gov/41922703/). *Nature*. [Gene Therapy / Novel Therapeutics]